Patients with stage III colorectal cancer were randomized to receive 6 or 12 months of adjuvant capecitabine. Treatment for 12 months was associated with improved relapse-free and overall survival compared with treatment for 6 months. Disease-free survival at 3 and 5 years was not significantly different between the two groups.
The use of adjuvant capecitabine for 12 months appears to confer relapse-free and overall survival benefits but does not improve disease-free survival.
– Neil Majithia, MD
This retrospective study evaluated the benefit derived from anti-EGFR therapy among patients with RAS/BRAF wild-type metastatic colorectal cancer with and without mucinous histology.
There was no meaningful benefit observed with anti-EGFR therapy among those with either left- or right-sided tumors with mucinous histology.
– Neil Majithia, MD
Now the White Oak resident is offering the details of her cancer battle through a feature in “On the Rise,” the national magazine of the nonprofit The Colon Club, with the aim of encouraging others to pay attention to their health.
Colorectal cancers diagnosed in early adulthood are genetically and clinically distinct, and potentially more aggressive, than colorectal tumors diagnosed at older ages, according to the results of a large analysis of four patient cohorts. The findings were published in the journal Cancer.
Among patients younger than 50 years old, colorectal tumors harbor different genetic mutations and histologic features than those seen in older patients, including synchronous metastases, microsatellite instability, and fewer BRAF V600 mutations, the researchers reported.
O Stoma Mia wrote:Drinking Coca-Cola and Diet Coke daily 'increases your risk of dying young'
GrouseMan wrote:I see a recent article in Science that will be published soon that there are concerns the possibility that in a few instances that so called checkpoint inhibitors could be the cause of "hyperprogression" seen in a few patients. Some cancer researchers wonder whether it is simply an illusion—whether the patients' tumors were destined to grow rapidly even before checkpoint inhibitor treatment. I have not received this issue yet and may have more details when I do.
Here is a link to the Summary from Science:
http://science.sciencemag.org/content/3 ... id=2739740
Next week in Atlanta at the annual meeting of the AARC, researchers will try to resolve how to pin down whether hyperprogression is real and, if so, how to identify which patients should not receive these increasingly popular drugs.
So we should keep watch on all the things coming out of AACR next week.
Update: More news on this topic. Have a look at the following Link:
https://www.sciencemag.org/news/2019/03 ... id=2741679
Kurzrock noted a clue in her patients with hyperprogression: Most had either mutations in EGFR or extra copies of MDM2 or MDM4, all known cancer genes. Although only some of the other teams studying hyperprogression have confirmed these findings, scientists working with Kurzrock are using cancer cell lines and mouse models that have alterations in these genes to see whether treating them with a checkpoint inhibitor somehow triggers the release of growth-promoting molecules.
“The main takehome is that there are a clear subset of patients that can be cured of recital cancer without surgery. We just need to better define who those patients are, so that we can comfortably offer this strategy to more patients without putting any of them at risk,” Nurkin told Cancer Network.
Users browsing this forum: Google [Bot], Valec and 25 guests